Clearside Biomedical, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLSD research report →
Companywww.clearsidebio.com
Clearside Biomedical, Inc. , a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema.
- CEO
- George Lasezkay
- IPO
- 2016
- Employees
- 32
- HQ
- Alpharetta, GA, US
Price Chart
Valuation
- Market Cap
- $2.15M
- P/E
- -0.06
- P/S
- 0.49
- P/B
- -0.03
- EV/EBITDA
- -3.93
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 85.55%
- Op Margin
- -689.76%
- Net Margin
- -780.90%
- ROE
- 55.47%
- ROIC
- -248.10%
Growth & Income
- Revenue
- $1.66M · -79.77%
- Net Income
- $-34,352,000 · -5.75%
- EPS
- $-7.05 · 11.32%
- Op Income
- $-28,882,000
- FCF YoY
- -28.94%
Performance & Tape
- 52W High
- $17.10
- 52W Low
- $0.31
- 50D MA
- $2.87
- 200D MA
- $8.22
- Beta
- 1.79
- Avg Volume
- 264.40K
Get TickerSpark's AI analysis on CLSD
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 13, 20 | WHITMORE BRADFORD T | buy | 50,000 |
| Aug 12, 20 | WHITMORE BRADFORD T | buy | 300,000 |
Our CLSD Coverage
We haven't published any research on CLSD yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLSD Report →